A phase II study of neuroimmunotherapy with subcutaneous low dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 2103-2105

  Lissoni, Paolo ^a   Bolis, S ^a   Brivio, F ^a   Fumagalli, L ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b CHIRON VACCINES   (Italy)

Author keywords

Hematologic malignancies; Immunotherapy; Interleukin 2; Leukemias; Lymphomas; Melatonin

Indexed keywords

MELATONIN; PINEAL BODY HORMONE; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; NEUROIMMUNOLOGY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN NODULE; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR IMMUNITY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELATONIN; MIDDLE AGED; NEOPLASM PROTEINS; NEUROIMMUNOMODULATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033884283     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rubinow DR: Brain, behavior and immunity: an interactive system. J Natl Cancer Inst Mongr 10: 79-82, 1990.
2. Jankovic BD: Neuroimmunomodulation. From phenomenology to molecular evidence. Ann NY Acad Sci 741: 3-38, 1994.
3. Del Prete G: Human Th1 and Th2 lymphocytes: their role in the physiopathology of atopy. Allergy 47: 450-455, 1991.
4. Sacerdote P and Panerai AE: Role of opioids in the modulation of TH1/TH2 responses. Neuroimmunomodulation 6: 422-423, 1999.
5. Maestroni GJM: The immunonendocrine role of melatonin. J Pineal Res 14: 1-10, 1993.
6. Maestroni GJM, Conti A and Lissoni P: Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4. Cancer Res 54: 4740-4743, 1994.
7. Bartsch C, Bartsch H and Lippert TH: The pineal gland and cancer: facts, hypotheses and perspectives. Cancer J 5: 194-199, 1992.
8. Molis TM, Spriggs LL, Yupiter Y and Hill SM: Melatonin modulation of estrogen-regulated proteins, growth factors and protooncogenes in human breast cancer. J Pineal Res 18: 93-103, 1995.
9. Whittington R and Faulds D: Interleukin-2. Drugs 46: 446-514, 1993.
10. Adler A, Chervenick PA and Whiteside TL et al: Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: feasibility of LAK generation in adult patients with active disease and in remission. Blood 71: 709.716, 1988.
11. Fefer A: Interleukin-2 in the treatment of hematologic malignancies. Cancer J Sci Am 3 (Suppl 1): S35-S36, 1997.
12. Meloni G, Vignetti M and Pogliani E et al: Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 3 (Suppl 1): S43-S47, 1997.
13. Lissoni P, Barni S and Tancini G et al: A randomised study with subcutaneous low-dose interleukin-2 versus interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69: 196-199, 1994.
14. Tesch H, Feller AC and Jucker M et al: Activation of cytokines in Hodgkin's disease. Ann Oncol 3 (Suppl 4): 13-16, 1992.
15. Macia J, Gomez X and Esquerda A et al: Value of the determination of TNF-alpha in the plasma of patients with non-Hodgkin's lymphoma. Leuk Lymphoma 20: 481-486, 1996.
16. Warzoka K, Bienvenu J and Ribeiro P et al: Plasma levels of tumor necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer 77: 2357-2362, 1998.
17. Viviani S, Negretti E and Orazi A et al: Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res 8: 347-354, 1990.